Ellie Merle
About Ellie Merle
Ellie Merle is a Biotech Analyst with extensive experience in the financial sector, currently working at UBS since 2020. She has previously held positions at Cantor Fitzgerald, Credit Suisse, and Deutsche Bank, contributing to her expertise in biotech equity research.
Current Role at UBS
Ellie Merle currently serves as a Biotech Analyst at UBS, a position she has held since 2020. In this role, she focuses on analyzing biotechnology companies and assessing their market potential. Her expertise in the biotech sector contributes to UBS's research and investment strategies.
Previous Experience at Cantor Fitzgerald
Before joining UBS, Ellie Merle worked at Cantor Fitzgerald as a Biotech Analyst from 2018 to 2020. During her two years at the firm, she provided insights and analysis on biotech stocks, helping clients make informed investment decisions in the rapidly evolving biotech landscape.
Experience at Credit Suisse
Ellie Merle was employed at Credit Suisse as a Biotech Equity Research Associate from 2015 to 2018. Over the course of three years, she conducted in-depth research on biotechnology firms, contributing to equity research reports that guided investment strategies.
Early Career at Deutsche Bank
Ellie Merle began her career at Deutsche Bank, where she worked as a Summer Analyst in 2013 for three months. She later served as a Biotech Equity Research Associate from 2014 to 2015 for one year. In these roles, she gained foundational experience in equity research and analysis within the biotech sector.
Education at Pomona College
Ellie Merle studied at Pomona College from 2010 to 2014, where she completed her undergraduate education. Her academic background provided her with the analytical skills necessary for her career in biotech analysis and equity research.